Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Gastrointestinal 1

Conditions

Melanoma 2Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Leflunomide × Dermatologic × Clear all
NCT06229340 2024-01-29

NТО-RAS

N.N. Petrov National Medical Research Center of Oncology

Phase 2 Recruiting
20 enrolled
DermatologicGastrointestinalThoracic

Lung Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01611675 2017-04-06

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Massachusetts General Hospital

Phase 1 Terminated
3 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡